Mysterious deepwater sharks, killed to make cosmetics, are granted new trade protections in ‘watershed moment’

At the CITES meeting in Samarkand on Nov. 28 more than 70 shark and ray species received stronger international trade protections, with gulper sharks moved to Appendix II (regulated trade) and several species uplisted to Appendix I (commercial trade ban). The global squalene market was estimated at $150M in 2023 (cosmetics accounting for >70% of demand), and extracting one ton of squalene historically required roughly 3,000 sharks — creating potential supply constraints for shark-derived squalene and regulatory risk for companies that still source it. The decision increases enforcement risk and creates a structural tailwind for plant- and bioengineered squalene suppliers and accelerates the shift toward sustainable substitutes for cosmetics and related industries.

Analysis

Market structure: The CITES uplisting is a targeted regulatory shock to shark-derived squalene supply but not a wholesale market collapse — global squalene market ≈ $150m (2023) with ~80% plant-sourced, implying shark-derived share ≈ $30m. Immediate beneficiaries are plant/bioengineered squalene producers and ESG-leading consumer staples (e.g., UL) that avoid supply disruption and reputational risk; deepwater fisheries and niche suppliers of animal-derived ingredients are direct losers. Pricing power will shift modestly to scalable biotech producers; if shark exports are materially curtailed, expect localized spot-price spikes (order-of-magnitude: +10–40% in 3–12 months) until capacity scales.

Risk assessment: Tail risks include aggressive enforcement/trade suspensions by CITES causing a sudden >25% drop in shark-derived supply within 60–180 days, forcing short-term shortages; conversely, supply-side biotech scale-up could compress margins for incumbents over 2–4 years. Hidden dependencies: small Asian brands with opaque labelling face litigation/reputational shocks and inventory write-downs; sovereign/fisheries-centric revenue in small states could face fiscal hits but limited systemic bond risk. Catalysts: published trade-suspension notices, major beauty brand disclosures, or quarterly capacity additions by Amyris/Croda-like suppliers will accelerate repricing.

Trade implications: Tactical trades: establish a 1–2% long in UL (Unilever, UL) over 6–12 months to capture ESG arbitrage and lower regulatory tail risk. Size a 0.5–1% notional position in Amyris (AMRS) via 3–6 month call spreads to play rapid adoption of bio-squalene (target 30–50% upside if adoption accelerates); if squalene spot >+15% in 60 days, add to AMRS. Reduce/trim by 50% exposure to small-cap beauty names where >5% revenue is traceable to shark-derived ingredients within 30 days; reallocate to large-cap personal-care suppliers. Sector tilt: rotate modestly into consumer staples/ingredient producers, reduce allocation to specialist marine-ingredient suppliers.

Contrarian angles: The market may be underestimating that 80% plant sourcing already limits near-term displacement, so immediate commodity-price moves could be muted — making current small-cap biotech names underowned and ripe for consolidation if demand shifts (M&A runway 12–36 months). Conversely, enforcement friction could create a black-market premium for shark oil, sustaining niche suppliers and legal risks for brands; also watch agricultural feedstock pressure (olive/sugarcane) which could lift related commodity prices and impact margins. Historical parallels (whale oil → kerosene; fur bans → synthetic textiles) suggest substitution wins concentrated industrial incumbents rather than a broad consumer-price shock.

Key Decisions for Investors

• Establish a 1–2% long position in Unilever (UL) with a 6–12 month horizon to capture reputational/ESG upside and lower regulatory supply risk; consider adding if UL underperforms FMCG peers by >3% on 30-day basis.
• Open a 0.5–1% notional position in Amyris (AMRS) via a 3–6 month call spread (buy calls / sell higher-strike calls) to play accelerated adoption of bioengineered squalene; scale up if squalene spot/ingredient index rises >15% within 60 days.
• Within 30 days, screen and reduce by 50% holdings in small-cap personal-care/beauty companies where >5% revenue is from animal-derived squalene (cut exposure to single-stock risk), reallocating proceeds to large-cap ingredient suppliers or UL.
• Set real-time alerts: (a) CITES trade-suspension notices or country-level permit declines >20% YoY; (b) squalene spot/ingredient price moves >+10% within 60 days — if triggered, increase bio-supplier exposure by another 0.5–1% and consider adding protective hedges (buy protective puts on exposed small-cap names).